A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.
Status:
Completed
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
Investigators are doing this research study to find out if methylphenidate (MPH) can help
people with Mild Cognitive Impairment (MCI) or mild dementia likely due to Alzheimer's
Disease (AD) and related disorders (ADRD).
The study drug MPH is approved by the U.S. Food and Drug Administration (FDA) to treat
Attention Deficit/Hyperactivity Disorder (ADHD), but MPH is not approved by the FDA to treat
Mild Cognitive Impairment or mild dementia related to Alzheimer's Disease. However, other
studies have been done in which MPH has been given to people with neurodegenerative dementias
and results have shown some improvement in these people's mood and cognition. Investigators
would like to see if MPH will help mood and cognition.
This study will take place completely virtually (with the option to come in for the first
visit to meet the study team). All study visits will occur over a secure videoconferencing
platform. All study materials will be shipped directly to the home of each participant.